Cancer immunotherapy: the past, the present and the future.
about
The potential of tumor-derived exosomes for noninvasive cancer monitoringClinical trials of dendritic cell-based cancer vaccines in hematologic malignanciesIn-depth method for the characterization of glycosylation in manufactured recombinant monoclonal antibody drugsThe immuno-oncology framework: Enabling a new era of cancer therapy.Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunityImmunotherapy for malignant gliomaUsefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma.Infiltrating CTLs are bothered by HLA-E on tumors.Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determinated by multiparametric single cell mass cytometry analysis.Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.Pivotal Advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response.Real-time monitoring of microdistribution of antibody-photon absorber conjugates during photoimmunotherapy in vivo.The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer RegistryCancer vaccines: a promising cancer therapy against all odds.Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directionsEmerging immunotherapies for glioblastomaNivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.Interactions between the immune system and cancer: a brief review of non-spatial mathematical models.Theoretical modeling techniques and their impact on tumor immunology.Adoptive immunotherapy of cancer: Gene transfer of T cell specificity.Can immuno-oncology offer a truly pan-tumour approach to therapy?Melanoma immunotherapy: historical precedents, recent successes and future prospects.Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.PD-1 blockade in renal cell carcinoma: to equilibrium and beyondCancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models.Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.Cardiovascular Complications Associated With Novel Cancer Immunotherapies.An Enzyme-Directed Imidazoquinoline for Cancer Immunotherapy.Advances in personalized cancer immunotherapy.Programming the immune checkpoint to treat hematologic malignancies.Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.Noncoding RNAs in Cancer Immunology.Neoantigen in esophageal squamous cell carcinoma for dendritic cell-based cancer vaccine development.Comparison of level of NKG2D ligands between normal and tumor tissue using multiplex RT-PCR.Transplantable subcutaneous hepatoma 22a affects functional activity of resident tissue macrophages in periphery.PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells.A study of tumour growth based on stoichiometric principles: a continuous model and its discrete analogue.
P2860
Q26796396-A912063B-1E84-4075-9062-7459FF7F6ECFQ26864603-F781635E-28EF-4A02-B9FB-78F9C75D7FFCQ33791817-3CB6383C-CC1E-415E-B43C-F68BF29F7603Q34284462-61C90785-BB27-4BC4-9311-97705FB2DA47Q34360174-C0943F09-C44A-4ADD-B473-F89F1ACE1FB7Q35114086-AD86265B-2A8B-4E81-9392-E2F9290BF07CQ35633563-06420D22-6AE6-401E-A0E1-F1AC2772CA11Q36038385-00880C5B-30AB-42E1-9FC4-8F2FE95F69F4Q36266655-79AD426B-B53E-47CC-B26B-7EAA62FB9706Q36301061-BE3532E5-920D-4A03-A10C-C7B0394DC635Q36394033-0FD218D7-C4DC-4A4E-91E7-FE8FBCD3FE09Q36397548-7C38FEFF-3792-472D-AEEB-911BFDDAA440Q36486902-DD06D5F9-08ED-4EF4-849A-1A03D6F710E1Q36839778-965813D8-8940-4A2D-B98C-593C26BA8AD0Q36844954-6D44B4FE-9CA3-444F-B327-3A953F3BEE47Q36954166-E0B376BE-B858-4317-B7A1-C37F899597B5Q37025105-3CF2DDBF-9A4B-43DD-9682-07E9D9EEF1DFQ37264931-8B8E80DB-F28C-415A-BD56-6D427092F7F8Q37708187-3FF69654-8B16-41DB-9087-74B075D65596Q37828405-104050A4-C1D6-4E0A-A3E7-DAD092C791F5Q37980749-DA80D986-3E8E-43D3-A6D8-3A8A86DB8688Q38037493-399E1761-3C54-47F4-B60D-49EC412A0660Q38081911-9E071F89-E163-4838-87BE-626632525D5CQ38082845-7328C161-2087-46C2-83C1-385B8B189608Q38194135-599A8D2E-349E-4137-BB83-8FD22BEE39CFQ38283974-4D967C7D-3578-44B8-A7C7-7762496DA76BQ38616707-79D65F5B-2767-4EA1-A6ED-7C6F67F3534BQ38672084-F831D195-F9C2-4487-94F3-3CAF700C3394Q38731522-95E201E5-DA0B-4CB4-A8EF-638B090D67A1Q38741706-FB212A9A-6734-47B1-9C20-9E3B1751B201Q38783946-D7946623-80F3-4CE6-ABEB-D44F153680DBQ38806070-58AD71BD-BF87-4744-A926-FA36E035997EQ38819982-CAA61B31-1DDA-4113-890D-45F2B5BB880DQ38837680-34710FC8-C06B-4BAB-AEC0-C28236E5B0BBQ38885490-B8712CAB-CCA9-4065-B6F6-D89CB27F7C11Q38960752-70E5683F-2A28-46D7-9797-E53356E6C27CQ40101035-66FFA5A1-3738-491C-9A48-D5040CFD232DQ42031076-AB128C7D-B4CF-424A-B6C6-56B8B6AA1559Q42253745-43B30678-45E9-40D0-816E-6E4E12389B68Q42976065-9934F78C-7CCD-4B1B-BD4D-1D16682472E5
P2860
Cancer immunotherapy: the past, the present and the future.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Cancer immunotherapy: the past, the present and the future.
@ast
Cancer immunotherapy: the past, the present and the future.
@en
type
label
Cancer immunotherapy: the past, the present and the future.
@ast
Cancer immunotherapy: the past, the present and the future.
@en
prefLabel
Cancer immunotherapy: the past, the present and the future.
@ast
Cancer immunotherapy: the past, the present and the future.
@en
P2860
P1476
Cancer immunotherapy: the past, the present and the future.
@en
P2093
Christopher R Parish
P2860
P304
P356
10.1046/J.0818-9641.2003.01151.X
P577
2003-04-01T00:00:00Z